New hope for Sjogren's: oral drug safety trial underway
NCT ID NCT04496960
First seen Jan 11, 2026 · Last updated May 19, 2026 · Updated 23 times
Summary
This study tests the safety of tofacitinib, an oral drug, in 23 adults with mild-to-moderate Sjogren's syndrome, an autoimmune disease. Participants take the drug or a placebo for 168 days and undergo various tests like exams, biopsies, and questionnaires. The goal is to see if tofacitinib is safe and tolerable for future use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SJOGREN'S SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.